4th Annual Computational Drug Development (CDD) for Biologics

4th Annual CDD for Biologics is organized by Hanson Wade and will be held from Nov 19 - 21, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America.

Pre-Conference Workshops:
Workshop A
Tuesday, November 19
9:00 am - 12:00 pm
Implementing Machine Learning and AI Technologies

Workshop B
Tuesday, November 19
1:00 pm - 4:00 pm
In-silico Immunogenicity Predictions (Hands-on Session)

Description:
What if you could improve on nature?
Biologics have always sought to exploit the ingenuity of the human body but now more than ever there is a chance to add to that. Powerful in silico tools exist to improve the selection of favorable molecules and optimize their attributes from early discovery through to late-stage candidate optimization.

The 4th annual CDD for Biologics Summit gathers the computational thought leaders in biopharma, academia and software providers along with the end-users in computational biology, structural biology and bioinformatics to debate how to add immediate value to biologics pipelines.

Join us to learn how to improve predictability of target ID and validation, better understand protein/protein interactions, enhance rational candidate selection and optimize developability characteristics. How could your pipeline benefit?

Welcome to the CDD for Biologics Summit
Recent advances in data availability and breakthroughs in computational power have given scientists new opportunities to optimize the discovery, design and developability of biotherapeutics.

However, with their utility lacking comparatively behind the small molecule space, there remains an ever-present need to address current capabilities amongst the scientific and operational challenges that exist.

With input from the likes of BMS, MedImmune, EMD Serono, Denali & Kadmon; CDD for Biologics has been specifically designed to help biopharma companies define strategies to further adapt these tools, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines.

Join us, as our expert speaker faculty shares the very latest insights into how these tools are being utilised to enhance cost-effectiveness, shorten biologics development timelines and accelerate program development.